Chugai Pharmaceutical Co.

 

Chugai Pharmaceutical Co., Ltd.

Type	Incorporation
Headquarters	Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo)
Website	[1]

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会) is a subsidiary drug manufacturer operating in Japan controlled by Hoffmann–La Roche, which owns 52% of the company. Previous to Roche's takeover in 2002, Chugai was a pioneering discoverer of many important pharmaceutical compounds. Osamu Nagayama is the current representative director president as well as CEO.

History

• 1961 developed patents for synthesis of vitamin A
• 1995 acute promyelocytic sphere of drug treatment leukemia "BESANOIDO" was released.
• 1996 anti-viral chemotherapeutic agent "HAIBIDDO" released (HIV reverse transcriptase inhibitor)
• 1997 HIV protease inhibitor "INBIRAZE" released
• 1999 immunosuppressive agent "SERUSEPUTO" released
• 2000 Release of an antiemetic drug developed to combat the side effects of chemotherapy
• 2001 Produced an anti-influenza virus "Tamiflu" (Roche)
• 2001 Discovered a malignant lymphoma target molecule "RITSUKISAN"
• 2001 Released "Herceptin," a novel breast cancer therapeutic

Other notable developments

Scientists at Chugai discovered an erythromycin-derived motilin agonist called Mitemcinal (aka GM-611 or 3'-N-dimethyl-11-deoxy-3'-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin.) Mitemcinal was believed to have strong prokinetic properties, similar to its parent molecule, but lack antibiotic properties. Presently, erythromycin is commonly used off-label for gastric motility indications such as Gastroparesis. If Mitemcinal can be shown to be as effective a prokinetic agent, it would represent a significant advance in the GI field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.

External links

• Chugai Pharmaceutical Co., Ltd. [2]
• The transfer of operations of the Company